헤르페스성 각막염(HK) : 세계 시장 전망, 역학, 경쟁 구도, 시장 예측 리포트(주요 32 시장), 2025-2035년

Global Herpetic Keratitis (HK) Market Outlook

Thelansis's "Global Herpetic Keratitis (HK) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report (Top 32 Markets) - 2025 To 2035" covers disease overview, epidemiology, kidney biopsy cases, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Herpetic Keratitis treatment modalities options for the 32 markets (North America, Europe, Middle East, Asia Pacific, Africa, South / Latin America).

Herpetic Keratitis (HK) Overview

Herpetic keratitis (HK) is a leading infectious cause of corneal blindness worldwide, caused predominantly by herpes simplex virus type 1 (HSV-1) - and less commonly HSV-2 - following primary ocular infection and subsequent latency establishment within the trigeminal ganglion, with recurrent reactivation driving progressive corneal damage. The pathophysiology involves both direct viral cytopathic injury to corneal epithelium and immune-mediated stromal inflammation, producing distinct clinical entities: epithelial keratitis - characterised by pathognomonic dendritic or geographic ulcers on fluorescein staining - stromal keratitis, endotheliitis, and neurotrophic keratopathy, each carrying distinct management implications. Patients present with unilateral eye pain, photophobia, lacrimation, blurred vision, and reduced corneal sensation - the latter a hallmark of herpetic aetiology. Diagnosis is primarily clinical, supported by slit-lamp biomicroscopy; PCR of corneal or aqueous samples confirms diagnosis in atypical presentations. Topical antivirals - ganciclovir gel or acyclovir ointment - are first-line for epithelial disease, while stromal keratitis requires judicious topical corticosteroids alongside antiviral cover to suppress immune-mediated injury. Oral acyclovir or valacyclovir prophylaxis significantly reduces recurrence frequency in patients with frequent relapses. Corneal transplantation addresses visually significant scarring in refractory cases. Prognosis worsens with recurrence frequency; long-term antiviral suppression, patient education regarding recurrence triggers, and regular ophthalmological surveillance are integral to preserving corneal integrity and visual function.

Key Highlights

• In China, incident cases of herpetic keratitis are projected to increase from approximately 206,184 in 2025 to nearly 221,717 by 2035, reflecting a growing disease burden.
• Recurrent HSV reactivation remains the primary driver of progressive corneal damage and vision impairment.
• Stromal keratitis and neurotrophic keratopathy continue to represent major causes of long-term visual morbidity.
• Long-term antiviral prophylaxis plays a critical role in reducing recurrence frequency and disease progression.
• Increasing awareness, earlier diagnosis, and improved ophthalmic management are supporting better disease outcomes.

Market Overview

• The China herpetic keratitis market is projected to grow from approximately $1,024.10 MN to $2,340.50 MN by 2035, reflecting substantial market expansion.
• Market growth is supported by:
• Increasing adoption of long-term antiviral suppression therapies
• Growing demand for advanced ophthalmic treatments for recurrent and severe disease
• Market value growth is driven by rising disease recurrence, prolonged treatment duration, and increased management of vision-threatening complications.
• Future market growth will depend on next-generation antiviral therapies, regenerative corneal treatments, and improved recurrence prevention strategies.

Market Definition:

• North America (United States, Canada)
• Europe (Austria, Belgium, Czech Republic, Denmark, Finland, France, Germany, Greece, Italy, Netherlands, Norway, Poland, Portugal, Russia, Spain, Sweden, Switzerland, United Kingdom)
• Middle East (Saudi Arabia, UAE, Kuwait, Turkey)
• Asia Pacific (Australia, China, Hong Kong, India, Indonesia, Japan, Malaysia, New Zealand, Philippines, Singapore, South Korea, Taiwan, Thailand, Vietnam)
• Africa (Egypt, Nigeria, South Africa, Morocco)
• South / Latin America (Argentina, Brazil, Chile, Colombia, Mexico, Peru)

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support
• As per Thelansis's policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2025-2035)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across the 32 markets (North America, Europe, Middle East, Asia Pacific, Africa, South / Latin America)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market's trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?

Countries Covered

• North America (United States, Canada)
• Europe (Austria, Belgium, Czech Republic, Denmark, Finland, France, Germany, Greece, Italy, Netherlands, Norway, Poland, Portugal, Russia, Spain, Sweden, Switzerland, United Kingdom)
• Middle East (Saudi Arabia, UAE, Kuwait, Turkey)
• Asia Pacific (Australia, China, Hong Kong, India, Indonesia, Japan, Malaysia, New Zealand, Philippines, Singapore, South Korea, Taiwan, Thailand, Vietnam)
• Africa (Egypt, Nigeria, South Africa, Morocco)
• South / Latin America (Argentina, Brazil, Chile, Colombia, Mexico, Peru)

Table of Contents

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risks, etc.

2. Disease Context

• Disease definition, classification, etiology and pathophysiology, drug targets, etc.

3. Epidemiology

• Key takeaways
• Incidence / Prevalence
• Diagnosed and Drug-Treated populations
• Comorbidities
• Other relevant patient segments

4. Market Size and Forecast

• Key takeaways
• Market drivers and constraints
• Drug-class specific trends
• Country-specific trends

5. Competitive Landscape

• Current therapies
• Key takeaways
• Dx and Tx journey/algorithm
• Key current therapies - profiles and KOL insights
• Emerging therapies
• Key takeaways
• Notable late-phase emerging therapies - profiles, launch expectations, KOL insights
• Notable early-phase pipeline

6. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

7. Regulatory and Reimbursement Environments (by country and payer insights)

8. Appendix (e.g., bibliography, methodology)